Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025
Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has scheduled its Q1 2025 financial results announcement for May 7, 2025, after market close.
The company's senior management team will host a webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss:
- First quarter 2025 financial performance
- Updates on corporate progress
Investors and interested parties can access the live webcast through the company's investor relations website at ir.revmed.com/events-and-presentations. A replay of the webcast will remain available on the website for at least 14 days following the live presentation.
Revolution Medicines (Nasdaq: RVMD), un'azienda oncologica in fase clinica avanzata specializzata nello sviluppo di terapie mirate per cancro RAS-dipendente, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 7 maggio 2025, dopo la chiusura del mercato.
Il team di gestione senior dell'azienda terrà un webcast alle 16:30 ET (13:30 PT) per discutere:
- Risultati finanziari del primo trimestre 2025
- Aggiornamenti sui progressi aziendali
Investitori e interessati potranno seguire il webcast in diretta attraverso il sito web delle relazioni con gli investitori all'indirizzo ir.revmed.com/events-and-presentations. La registrazione del webcast sarà disponibile sul sito per almeno 14 giorni dopo la presentazione dal vivo.
Revolution Medicines (Nasdaq: RVMD), una empresa oncológica en etapa clínica avanzada enfocada en desarrollar terapias dirigidas para cánceres dependientes de RAS, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 7 de mayo de 2025, después del cierre del mercado.
El equipo directivo senior de la compañía realizará una transmisión en vivo a las 4:30 p.m. ET (1:30 p.m. PT) para discutir:
- Desempeño financiero del primer trimestre de 2025
- Actualizaciones sobre el progreso corporativo
Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través del sitio web de relaciones con inversionistas en ir.revmed.com/events-and-presentations. La repetición de la transmisión estará disponible en el sitio web durante al menos 14 días después de la presentación en vivo.
Revolution Medicines (나스닥: RVMD)는 RAS 의존성 암을 대상으로 하는 표적 치료제 개발에 집중하는 후기 임상 단계의 종양학 회사로, 2025년 5월 7일 시장 마감 후 2025년 1분기 재무 실적 발표를 예정하고 있습니다.
회사의 고위 경영진은 동부 표준시 오후 4시 30분 (태평양 표준시 오후 1시 30분)에 웹캐스트를 진행하여 다음 내용을 논의할 예정입니다:
- 2025년 1분기 재무 성과
- 기업 진행 상황 업데이트
투자자 및 관심 있는 분들은 회사의 투자자 관계 웹사이트 ir.revmed.com/events-and-presentations를 통해 라이브 웹캐스트에 접속할 수 있습니다. 라이브 발표 후 최소 14일간 웹캐스트 다시보기 서비스가 제공됩니다.
Revolution Medicines (Nasdaq : RVMD), une société oncologique en phase clinique avancée spécialisée dans le développement de thérapies ciblées pour les cancers dépendants de RAS, a prévu d'annoncer ses résultats financiers du premier trimestre 2025 le 7 mai 2025, après la clôture du marché.
L'équipe de direction senior de la société animera un webinaire à 16h30 ET (13h30 PT) pour discuter de :
- Les performances financières du premier trimestre 2025
- Les mises à jour sur les progrès de l'entreprise
Les investisseurs et parties intéressées peuvent accéder au webinaire en direct via le site des relations investisseurs de la société à ir.revmed.com/events-and-presentations. La rediffusion du webinaire restera disponible sur le site pendant au moins 14 jours après la présentation en direct.
Revolution Medicines (Nasdaq: RVMD), ein klinisch fortgeschrittenes Onkologieunternehmen, das sich auf die Entwicklung zielgerichteter Therapien für RAS-abhängige Krebserkrankungen spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 7. Mai 2025 nach Börsenschluss geplant.
Das Senior-Management-Team des Unternehmens wird um 16:30 Uhr ET (13:30 Uhr PT) eine Webkonferenz abhalten, um Folgendes zu besprechen:
- Finanzielle Leistung im ersten Quartal 2025
- Aktuelle Informationen zum Unternehmensfortschritt
Investoren und Interessierte können über die Investor-Relations-Website des Unternehmens unter ir.revmed.com/events-and-presentations auf das Live-Webcast zugreifen. Eine Aufzeichnung des Webcasts wird mindestens 14 Tage nach der Live-Präsentation auf der Website verfügbar bleiben.
- Late-stage clinical status indicates advanced development progress in oncology therapeutics
- Focus on targeted therapies for RAS-addicted cancers shows clear market positioning
- None.
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
When will Revolution Medicines (RVMD) release Q1 2025 earnings?
What time is Revolution Medicines (RVMD) Q1 2025 earnings call?
How can I listen to RVMD's Q1 2025 earnings webcast?
What will Revolution Medicines discuss in their May 7 earnings call?
What type of cancer treatments does Revolution Medicines (RVMD) develop?
